DANTE

A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340)– The DANTE Trial

Die Studie eignet sich für: Adenokarzinom des Magens und gastroösophagealen Übergangs

Weitere Informationen